NU Skin Enterprises Inc

NU Skin Enterprises Inc(NUS)股票分析

$4.990

+0.308 (+6.17%)收盤時

Loading chart…
最高
5.130
開盤
4.830
成交量加權均價
4.98
成交量
646.13K
市值
536.41M
最低
4.830
成交金額
3.22M
企業價值/稅息折舊攤銷前利潤(TTM)
2.16

Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. It has nine segments, consisting of its seven geographic Nu Skin segments - Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan - and two Rhyz segments - Manufacturing and Rhyz Other. Its beauty & skincare solutions include acne and blemishes, anti-aging, dark circles and puffiness, discoloration, dry skin, lines and wrinkles, and oily skin and pores. Its health & wellness solutions include gut health, bone and joint health, brain health, energy and stamina, heart health, immunity support, and protein and fitness. It offers various beauty devices, including ageLOC LumiSpa, Nu Skin RenuSpa iO and Prysm iO. Its ageLOC LumiSpa includes products such as LumiSpa iO Superpower Kit, ageLOC Rose Gold LumiSpa iO, LumiSpa Rose Gold Accent Twin Pack, and others.

AI 分析 of NU Skin Enterprises Inc (NUS)

買進

NU Skin Enterprises Inc (NUS) is a good buy right now, trading at $4.78, which is significantly below its 52-week high of $11.67. The forward P/E ratio is 4.008, indicating potential undervaluation compared to future earnings. Additionally, the stock has shown a recent positive trend with a 5-day change of +1.92% and a 20-day change of +3.24%. However, a key risk is the net margin, which has dropped to -78.03% in Q2 2026, indicating potential ongoing profitability issues that investors should monitor closely.

分析師評級(6)

買進
3 買進
1 持有
2 賣出
目前: 4.99
最低
—
平均
—
最高
—

DA Davidson

2024-12-20

目標價

$7

持有

Citigroup

2024-10-22

目標價

$6.75

持有

DA Davidson

2024-08-12

目標價

$11

持有

Citigroup

2024-08-09

目標價

$12

持有

DA Davidson

2024-05-09

目標價

$13

持有

估值指標

NU Skin Enterprises Inc(NUS)目前預期本益比為 4.12,5 年平均預期本益比為 11.03。

預期本益比

低估
5 年均值 P/E
11.03
目前P/E
4.12
高估
16.12
低估
5.93

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
5.36
目前EV/EBITDA
2.16
高估
8.39
低估
2.34

預期股價營收比

低估
5 年均值 P/S
0.51
目前P/S
0.16
高估
0.84
低估
0.18

Alphio AI 對 NUS 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%NUS

$6.63

情境價格

基

基準

基準 · 50%NUS

$6.29

情境價格

悲

悲觀

悲觀 · 25%NUS

$4.75

情境價格

持有 NUS 的大戶

C

Castleknight Management LP

+ 持有NUS

-5.48%

3個月報酬率

事件時間軸

2026-08-10 (ET)

16:30:00

Sees Q3 Revenue of $310M to $340M

16:30:00

Cuts FY26 Revenue View to $1.28B-$1.35B

2026-05-07 (ET)

16:10:00

Company Confirms FY26 Revenue Outlook of $1.35B to $1.5B

16:10:00

Nu Skin Q1 Revenue at $320.6M, Below Estimate

16:10:00

Sees Q2 Revenue of $330M-$360M

資訊

NUS 常見問題 —— 由 Alphio AI 解答

Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. It has nine segments, consisting of its seven geographic Nu Skin segments - Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan - and two Rhyz segments - Manufacturing and Rhyz Other. Its beauty & skincare solutions include acne and blemishes, anti-aging, dark circles and puffiness, discoloration, dry skin, lines and wrinkles, and oily skin and pores. Its health & wellness solutions include gut health, bone and joint health, brain health, energy and stamina, heart health, immunity support, and protein and fitness. It offers various beauty devices, including ageLOC LumiSpa, Nu Skin RenuSpa iO and Prysm iO. Its ageLOC LumiSpa includes products such as LumiSpa iO Superpower Kit, ageLOC Rose Gold LumiSpa iO, LumiSpa Rose Gold Accent Twin Pack, and others. It operates in the Consumer Non-Cyclicals sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

NU Skin Enterprises Inc (NUS) is a good buy right now, trading at $4.78, which is significantly below its 52-week high of $11.67. The forward P/E ratio is 4.008, indicating potential undervaluation compared to future earnings. Additionally, the stock has shown a recent positive trend with a 5-day change of +1.92% and a 20-day change of +3.24%. However, a key risk is the net margin, which has dropped to -78.03% in Q2 2026, indicating potential ongoing profitability issues that investors should monitor closely.

6 analysts cover NUS: 3 rate it Buy, 1 Hold and 2 Sell.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易